newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics